Oculis Holding AG Ordinary shares

Yahoo Finance • last year

Oculis Reports Q3 2023 Financial Results and Provides Company Update

Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular e... Full story

Yahoo Finance • last year

Oculis to Present at Upcoming November Investor Conferences

ZUG, Switzerland, and BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD,... Full story

Yahoo Finance • last year

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

ZUG, Switzerland and BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that t... Full story

Yahoo Finance • last year

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

OCS-01’s positive results in Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME) were presented as a late-breaking abstract showing that the trial met primary and secondary endpoints with robust statistical significanceOn... Full story

Yahoo Finance • last year

Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

ZUG, Switzerland, and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that... Full story

Yahoo Finance • last year

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.... Full story

Yahoo Finance • last year

Oculis to Present at Upcoming September Investor Conferences

ZUG, Switzerland, and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD,... Full story

Yahoo Finance • last year

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back of the eye indications: positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular e... Full story

Yahoo Finance • last year

Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023

R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte New York Palace Hotel and onlineCo-principal investigators, Dr.David S. Boyer and Dr. Arshad M. Khanani, for Phase 3 DIAMOND trial of... Full story

Yahoo Finance • 2 years ago

Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares

ZUG, Switzerland and BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the underwriters of its previ... Full story

Yahoo Finance • 2 years ago

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn Loftsson. OPTIREACH is behind Oculis’ lead candidate OCS-01, currently in Phas... Full story

Yahoo Finance • 2 years ago

Oculis Co-founders Selected as Finalists in European Inventor Award 2023

Professors Einar Stefánsson and Thorsteinn Loftsson, Oculis’ co-founders, nominated in ‘Research’ category of prestigious European Patent Office awards Nominated in recognition of research developing the OPTIREACH solubilizing formulation... Full story

Yahoo Finance • 2 years ago

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team strengthened by US-based hires, including Dr. F... Full story

Yahoo Finance • 2 years ago

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a vi... Full story